This cluster reflects a maturing systems-biology view of Alzheimer's Disease (AD) that moves beyond the classic amyloid cascade toward an integrated network of genetic, epigenetic, biophysical, and physiological drivers converging on amyloid-beta and tau pathology. Amyloid-beta remains a central hub, generated via amyloidogenic processing of amyloid precursor protein and modulated by genetic variants in APP, PSEN1, PSEN2, and APOE—with the APOE4 allele acting as the strongest genetic risk factor, accelerating both amyloid deposition into extracellular plaques and tau hyperphosphorylation into intracellular neurofibrillary tangles. Tau pathology is mechanistically linked to STAT3 signaling, which regulates APP processing, mediates tau phosphorylation, and governs neuronal survival, positioning STAT3 as a tractable node for disease-modifying drug development. Downstream, these protein aggregates produce measurable biophysical signatures—altered tissue conductivity, dielectric response time, and structural inhomogeneity driven by elevated water content—suggesting biophysical/electromagnetic tissue profiling as an emerging diagnostic modality complementing fluid and imaging biomarkers like phosphorylated tau.
A second major thread concerns post-transcriptional and epigenetic regulation via non-coding RNAs. MicroRNAs and long non-coding RNAs are highlighted as dual-function regulators that can either protect against or exacerbate neural cell damage, modulating gene expression, cellular proliferation, angiogenesis, and intercellular communication—processes relevant to both neurodegeneration and shared cellular vulnerability across cancer and other age-related diseases. Circular RNAs extend this regulatory layer, implicated in autophagy, synaptic maintenance, and neuronal survival, marking non-coding RNA classes as candidate biomarkers and therapeutic targets. Alternative splicing is similarly framed as a central regulatory axis shaping neuronal function and susceptibility, reinforcing RNA-level dysregulation as a unifying upstream mechanism preceding protein aggregation.
A third convergent trend is genetic geroscience—an emerging paradigm using modern statistical models (e.g., Pan and colleagues) to identify pleiotropic genetic variants linking AD to broader age-related comorbidities such as coronary heart disease, hyperlipidemia, and cancer. This reframes AD not as an isolated neurodegenerative entity but as one manifestation of shared aging biology, consistent with geroscience's broader thesis that aging processes are common contributors to multiple chronic diseases. Physiological modulators—particularly sleep and the glymphatic/aquaporin-4 pathway—are positioned as bidirectional, mechanistic links between systemic aging processes and amyloid/tau clearance, nominating sleep optimization and non-invasive physical interventions as convergent, low-risk strategies for disease modification alongside pharmacological approaches like anti-amyloid antibodies (e.g., donanemab).
Collectively, these entities describe a translational trajectory: from genetic risk (APOE4, APP/PSEN variants) and RNA-level regulatory dysfunction, through STAT3-mediated signaling and glymphatic/sleep-dependent clearance failure, to measurable biophysical and fluid biomarkers, culminating in therapeutic strategies spanning anti-amyloid immunotherapy, STAT3-targeted small molecules, non-coding RNA modulators, and lifestyle/physical interventions—unified under a geroscience framework that treats AD as intertwined with systemic aging pathology.